MRI is a uniquely valuable tool for studying the brain because MRI scans are noninvasive and can provide information at relatively high spatial resolution (< 100 µm) and temporal resolution (~1 s) from living specimens. Functional imaging (fMRI) of brain activity is possible with MRI methods sensitive to cerebral hemodynamics 1 . The most common fMRI technique, blood oxygen level-dependent (BOLD) fMRI, is based on oxygenation of hemoglobin, an endogenous oxygen-sensitive MRI contrast agent present in the blood 2 . Although BOLD fMRI has had a tremendous impact in neuroscience, the method provides only a slow and indirect readout of neural activity, owing to the complexity of neurovascular coupling 3 . Considerably more precise measurements of brain function would be possible with MRI sensors that were directly and rapidly responsive to neurochemicals involved in the brain's information processing 4 .
A r t i c l e s
MRI is a uniquely valuable tool for studying the brain because MRI scans are noninvasive and can provide information at relatively high spatial resolution (< 100 µm) and temporal resolution (~1 s) from living specimens. Functional imaging (fMRI) of brain activity is possible with MRI methods sensitive to cerebral hemodynamics 1 . The most common fMRI technique, blood oxygen level-dependent (BOLD) fMRI, is based on oxygenation of hemoglobin, an endogenous oxygen-sensitive MRI contrast agent present in the blood 2 . Although BOLD fMRI has had a tremendous impact in neuroscience, the method provides only a slow and indirect readout of neural activity, owing to the complexity of neurovascular coupling 3 . Considerably more precise measurements of brain function would be possible with MRI sensors that were directly and rapidly responsive to neurochemicals involved in the brain's information processing 4 .
The challenging process of developing sensors for next-generation neuroimaging could be greatly accelerated using advanced molecular engineering techniques. Directed evolution is a molecular engineering method that employs successive rounds of mutagenesis and selection to generate proteins with novel functionality, starting from a molecule with some of the desired properties of the end product 5 . This technique could be applied to evolve MRI sensors from proteins that are magnetically active (for example, paramagnetic) and have tunable ligand-binding or catalytic properties.
The flavocytochrome P450-BM3 (BM3), a fatty acid hydroxylase from Bacillus megaterium, contains a paramagnetic iron atom embedded in a solvent-accessible substrate-binding pocket, suggesting that it could produce ligand-dependent MRI signal changes. BM3's binding specificity is also highly tunable, as demonstrated by previous efforts to identify novel enzymatic activities through directed evolution of this protein [6] [7] [8] [9] . If BM3 variants could be engineered to act as MRI sensors, they would be genetically encodable, an added advantage over synthetic molecular imaging agents.
We sought to apply directed evolution of BM3 to develop MRI sensors for a key signaling molecule in the brain, the neurotransmitter dopamine. To our knowledge, no MRI contrast agent for sensing dopamine (or any other neurotransmitter) currently exists, but there is considerable interest in measuring dopamine-related activity by MRI 10 . Dopamine is of particular significance because of its roles in learning, reward and motor coordination 11 , and because the dysfunction of dopaminergic systems underlies addiction 12 and several neurodegenerative diseases 13 . Existing techniques for measuring dopamine in vivo are either invasive point-measurement methods [14] [15] [16] or positron emission tomography procedures 17 with low spatial and temporal resolution. MRI could be used successfully for dopamine measurement if combined with an imaging agent capable of responding quickly, reversibly and specifically to extracellular dopamine fluctuations from <1 µM to tens of micromolar 18, 19 . To be comparable with established functional brain imaging techniques, interaction of dopamine with the probe should also produce image signal changes on the order of 1% or more in vivo 20 . Here we show that directed evolution of BM3 is capable of producing dopamine sensors that largely meet these specifications.
RESULTS

P450 BM3 reports ligand binding in MRI
To evolve dopamine probes for MRI, we focused on the heme domain of BM3 (BM3h), a 53-kDa moiety that is catalytically inactive in the absence of the full protein's reductase domain 21 . BM3h contains a Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine A r t i c l e s single iron(III) atom (mixed spin 1/2 and 5/2) 22 bound to a hemin prosthetic group and axially coordinated by residue Cys400 on the protein. In the absence of substrates, the remaining coordination site is filled by a water molecule 23 . Interaction of the heme iron with exchanging water molecules at this axial site promotes T 1 relaxation in aqueous solutions 24 and is therefore predicted to modulate MRI contrast. To determine the extent of this effect, we used a spin echo pulse sequence in a 4.7-T MRI scanner to measure the proton relaxation rate as a function of protein concentration in PBS; the slope of this relationship (T 1 relaxivity, or r 1 ) provides a standard measure of the strength of a contrast agent. For BM3h in the absence of ligands, an r 1 value of 1.23 ± 0.07 mM −1 s −1 was obtained. Addition of a saturating quantity of the natural BM3 substrate, arachidonic acid (400 µM concentration), resulted in an r 1 of 0.42 ± 0.05 mM −1 s −1 (Fig. 1a) . This ligand-induced decrease in relaxivity, probably arising from the displacement of water molecules at the BM3h heme, enabled quantitative sensing of arachidonic acid using MRI (Fig. 1b) and suggested that BM3h could serve as a platform for molecular sensor engineering.
We next tested whether dopamine or related compounds could serve as unnatural ligands to BM3h when applied at high enough concentrations. As measured by MRI, addition of 1 mM dopamine to BM3h in fact induced a drop in r 1 to 0.76 ± 0.03 mM −1 s −1 (Fig. 1a) . Binding of arachidonic acid is known to induce a change (blue shift) in BM3h's optical absorbance spectrum because of perturbation of the electronic environment of the heme chromophore 25 . To determine whether the relaxation change induced by dopamine also reflects interaction with the BM3h heme, we measured optical spectra of the protein in the presence and absence of 1 mM dopamine. The interaction produced a small but clearly discernable red shift of λ max , from 419 to 422 nm (Fig. 1c) , indicative of ligand coordination to the heme iron 25 . This suggests that dopamine (at 1 mM) directly replaces water as an axial metal ligand in the BM3h substrate-binding pocket and that directed evolution of BM3h binding specificity could therefore improve the protein's relative affinity for dopamine. In addition to providing mechanistic insight, the correspondence between optical and MRI measurements of ligand binding to BM3h implied that either modality could be used to obtain quantitative binding parameters. We monitored the difference between absorption at two wavelengths as a function of ligand concentration to determine binding isotherms for arachidonic acid and dopamine (Fig. 1d,e) . For BM3h, the apparent K d for arachidonic acid was 6.8 ± 0.5 µM; the K d for dopamine was 990 ± 110 µM. Goals for the production of BM3h-based MRI sensors thus included decreasing the affinity for arachidonic acid, increasing the dopamine affinity by at least two orders of magnitude and maintaining or enhancing the relaxivity changes observed upon ligand binding.
Directed evolution of dopamine-responsive BM3h variants
To create an MRI sensor for dopamine using directed evolution, we developed a customized screening methodology (Fig. 2a) . Results shown in Figure 1 suggested that either MRI-based or optical assays could be used to distinguish BM3h mutants with differing ligand affinities. We chose an absorbance assay for our screen because lower protein concentrations (~1 µM) could be used in this format. Input to each round of screening consisted of a library of BM3h mutants, each with an average of one to two amino acid substitutions, generated by error-prone PCR from the wild-type (WT) gene or a previously selected mutant. We transformed DNA libraries into Escherichia coli. We grew and induced approximately 900 randomly selected clones in microtiter plate format, then prepared cleared lysates for optical titration with dopamine and arachidonic acid in a plate reader. Titration data were analyzed to determine K d values for both ligands. An average of 79% of assayed mutants had sufficient protein levels (absorbance signal > 30% of parent) and clean enough titration curves (r 2 > 0.8) for K d estimation. Mutant affinities appeared to be distributed randomly about the dissociation constant measured for the corresponding parent protein, but we were able to identify individual clones with desired affinity changes in each round (Fig. 2b) . From each screen, we chose eight to ten mutants on the basis of their estimated K d s, purified them in bulk, re-titrated them to obtain more accurate estimates of their dopamine and arachidonic acid affinities, and examined them with MRI to ensure that robust ligand-induced changes in r 1 could be detected. On the basis of these assays, we chose as a parent for the next round of evolution the mutant showing the best combination of relaxivity changes, improved dopamine affinity and decreased affinity for arachidonic acid.
After carrying out the screening strategy over multiple rounds, we found a steady trend in the distribution of K d values toward greater affinity for dopamine and less affinity for arachidonic acid (Fig. 2b-d) . Little change in binding cooperativity was observed, and changes in partial saturation generally occurred over 100-fold ranges of dopamine concentrations. Five rounds of evolution yielded a BM3h variant with eight mutations (Fig. 2e) , four near the ligand-binding pocket and four at distal surfaces of the protein. One residue (Ile263) was first mutated to threonine (third round), then to alanine (fourth round). The clones selected from rounds 1, 3 and 5 had two new mutations each. We did not determine the individual contributions of We computed the optical signals used for titration analysis by subtracting the minimum from the maximum of difference spectra (arrowheads in d) under each set of conditions. Error bars in a, b and e reflect s.e.m. of three independent measurements (errors in e were smaller than the symbols).
A r t i c l e s these mutations to the observed changes in affinity. We introduced the mutation I366V by site-directed mutagenesis before the fifth round to enhance thermostability and tolerance of BM3h to further mutation 26, 27 ; it did not noticeably affect dopamine binding affinity.
The mutant proteins selected after the fourth and fifth rounds of evolution, denoted BM3h-8C8 and BM3h-B7, had optically determined dissociation constants of 8.9 ± 0.7 µM and 3.3 ± 0.1 µM, respectively, for dopamine, and 750 ± 140 µM and 660 ± 80 µM, respectively, for arachidonic acid. The T 1 relaxivity of BM3h-8C8 was 1.1 ± 0.1 mM −1 s −1 in the absence of ligand and 0.17 ± 0.03 mM −1 s −1 in the presence of 400 µM dopamine (Fig. 3a) . For BM3h-B7, the corresponding r 1 values were 0.96 ± 0.13 mM −1 s −1 and 0.14 ± 0.04 mM −1 s −1 . Both sensor variants showed a dopamine concentration-dependent decrease in T 1 -weighted MRI signal (up to 13% with 28.5 µM protein) that could be fitted by binding isotherms with estimated K d values of 4.9 ± 2.7 µM for BM3h-8C8 and 2.7 ± 2.9 µM for BM3h-B7 (Fig. 3b,c) . For both BM3h variants, the stability, reversibility and rate of dopamine binding were established using spectroscopic assays ( Supplementary Figs. 1 and 2) .
We investigated the reporting specificities of BM3h-8C8 and BM3h-B7 for dopamine by measuring MRI signal changes that resulted from incubation of 28.5 µM of each protein with 30 µM of either dopamine or one of eight other neuroactive molecules: norepinephrine (a neurotransmitter formed by catalytic hydroxylation of dopamine), 3,4-dihydroxy-l-phenylalanine (DOPA, the biosynthetic precursor to dopamine), serotonin, glutamate, glycine, γ-aminobutyric acid (GABA), acetylcholine and arachidonic acid (Fig. 3d) . Of these potential ligands, only dopamine, norepinephrine and serotonin elicited . Mutant proteins identified by rounds 4 (8C8) and 5 (B7) were considered to be end products of the screening procedure. (e) X-ray crystal structure 34 of WT BM3h (gray; heme group shown in orange) bound to palmitoleic acid (black), indicating the locations of amino acid substitutions accumulated during directed evolution of enhanced dopamine binding affinity. Each mutation's location is marked with a blue sphere and a label color-coded according to the parent protein in which the substitution was first identified (see legend for b). The previously characterized I366V mutation (asterisk) was incorporated between screening rounds 4 and 5 to improve the thermostability of the engineered proteins. substantial changes in the T 1 relaxation rate (1/T 1 ). For BM3h-8C8, the 1/T 1 reductions produced by norepinephrine and serotonin were 0.0076 ± 0.0023 s −1 and 0.0041 ± 0.0020 s −1 , respectively, compared to 0.0182 ± 0.0006 s −1 for dopamine; for BM3h-B7, norepinephrine and serotonin induced 1/T 1 decreases of 0.0112 ± 0.0024 s −1 and 0.0171 ± 0.0005 s −1 , respectively, compared to 0.0208 ± 0.0002 s −1 for dopamine. We measured the affinities of BM3h-based dopamine sensors for these competitors spectroscopically (Fig. 3d, inset) . For BM3h-8C8, measured K d s were 44 ± 3 µM and 80 ± 8 µM for norepinephrine and serotonin, respectively, and for BM3h-B7 the K d values were 18.6 ± 0.4 µM and 11.8 ± 0.1 µM, respectively. Although both BM3h-8C8 and BM3h-B7 show substantially higher affinity for dopamine than for norepinephrine (fivefold and sixfold, respectively) or for serotonin (ninefold and fourfold, respectively), the BM3h-8C8 variant is more specific for sensing dopamine at concentrations above 10 µM. In settings where dopamine is known to be the dominant neurotransmitter, BM3h-B7 may provide greater overall sensitivity. The specificity data also provided a possible indication of the geometry of dopamine binding to the evolved BM3h proteins. Only monoamines showed affinity for BM3h-8C8 and BM3h-B7, whereas two catechols that lack primary amines, epinephrine and 3,4-dihydrophenylacetic acid, showed no measurable affinity (data not shown). Combined with the spectral evidence that dopamine directly coordinates the BM3h heme (Fig. 1c) , the titration results therefore suggest that the dopamine amine may serve as an axial ligand to the BM3h heme in the sensor-analyte complexes we examined.
BM3h-based sensors detect dopamine released from PC12 cells
We asked whether BM3h mutants produced by directed evolution could sense dopamine release in a standard cellular model of dopaminergic function. We applied an established protocol 28 to test the ability of our sensors to measure dopamine discharge from PC12 cells stimulated with extracellular K + (Fig. 4a) . Cells were cultured in serum-free medium supplemented with dopamine to promote packaging of the neurotransmitter into vesicles. After pelleting and washing, we resuspended cells in a physiological buffer containing 32 µM BM3h-B7 and either 5.6 or 59.6 mM K + (cells in the low-K + condition were osmotically balanced with Na + ). T 1 -weighted MRI images (spin echo TE/TR = 10/477 ms) obtained with BM3h-B7 showed a 4.0 ± 0.5% reduction in signal intensity in the supernatant of K + -stimulated cells, compared with cells for which isotonic Na + was used as control (Fig. 4b) . This corresponded to a 54 ± 4% decrease in sensor r 1 (Fig. 4c) . Given the dopamine dissociation constant of BM3h-B7 and its relaxivities under ligand-free and dopamine-saturated conditions, and assuming negligible dilution of the sensor after mixing with cells, we estimated supernatant dopamine concentrations of 60.3 ± 7.9 µM for stimulated cells and 22.2 ± 1.1 µM for controls. These estimates were in reasonable agreement with an independent quantification of dopamine release measured using an enzyme-linked immunosorbent assay (ELISA), which yielded concentrations of 54 ± 9 µM and 13 ± 2 µM for stimulated and control cells, respectively (Fig. 4d) . We were also able to use BM3h-8C8 to image dopamine release from PC12 cells. Under experimental conditions similar to above, BM3h-8C8 had a 37 ± 2% reduction in r 1 in the supernatant of K + -stimulated cells relative to Na + controls (Supplementary Fig. 3 ).
Dopamine detection in the brain of living rats
As an initial test of the ability of BM3h-based sensors to measure dopamine concentrations in intact animals, we injected BM3h-8C8 in the presence or absence of exogenous dopamine into the brains of anesthetized rats. We chose this simple experimental protocol for validation of the sensor because it guaranteed the presence of reproducible and unambiguous micromolar-level dopamine concentrations, suitable for evoking robust responses from our sensors in vivo. We obtained T 1 -weighted MRI scans (fast spin echo TE/TR 14/277 ms, 8.9 s per image) continuously during 0.5-µl-min −1 paired infusions of 500 µM BM3h-8C8 with and without 500 µM dopamine, via cannulae implanted stereotaxically into the left and right striatum. Dopamine-dependent contrast changes were apparent in images obtained during and after the injection period (Fig. 5a) . We quantified MRI changes across multiple trials in striatal regions of interest (ROIs) that were reliably (though inhomogeneously) filled by convective spread of the contrast agent from the cannula tips (~1.5 mm radius). Consistent with results obtained in vitro, addition of dopamine dampened the observed MRI intensity enhancement by approximately 50% (Fig. 5b) ; the effect was significant (t-test, P = 0.003, n = 7). We performed the same paired infusion procedure with WT BM3h, which has very low affinity for dopamine (K d ~1 mM). As expected, the time course of the MRI signal during and after the WT BM3h injection period (Fig. 5c) was not significantly affected by the presence or absence of dopamine (t-test, P = 0.8, n = 5), indicating that the dopamine-dependent signal differences shown in Figure 5b require the presence of a micromolar-affinity dopamine sensor and cannot be explained by physiological or biochemical effects of dopamine itself. Moreover, infusion of 500 µM dopamine alone into the brain produced no noticeable signal changes in an equivalent experiment (data not shown). Histological analysis showed minimal evidence of toxicity due to these procedures (Supplementary Fig. 4) . Using relaxivity values measured for BM3h-8C8 in vitro, we estimated maximal concentrations of 89 ± 19 µM BM3h-8C8 and 75 ± 28 µM dopamine from the data of Figure 5b , averaged across the striatal ROIs. The ability to quantify BM3h-8C8 concentration on the basis of its T 1 enhancement in the absence of elevated dopamine represents an advantage of this sensor's 'turn-off ' mechanism.
To test whether BM3h-8C8 could detect release of endogenous neurotransmitters in the rat brain, we acquired MRI data during co-infusion of the dopamine sensor with elevated concentrations of K + , a depolarizing chemical stimulus shown previously to release large amounts of A r t i c l e s dopamine into the striatum 29, 30 . We chose K + over pharmacological stimuli to obviate potential solubility-or viscosity-related artifacts in the experimental paradigm. K + itself had no effect on r 1 of the BM3h variants (data not shown). In the stimulation experiments, three 5-min blocks of high-K + (153 mM) infusion alternated with 10-min 'rest' periods during which we administered a low-K + solution (3 mM, osmotically balanced with Na + ). Both high-and low-K + solutions were delivered at a rate of 0.2 µl min −1 and also contained 500 µM BM3h-8C8, ensuring that a relatively constant concentration of dopamine sensor was present throughout the procedure. We acquired T 1 -weighted MRI scans continuously as for the exogenous dopamine infusion experiments. To control for effects unrelated to neurotransmitter sensing by the contrast agent (potentially including K + -induced edema or hemodynamic responses incompletely suppressed by the T 1 -weighted spin echo pulse sequence), we paired each striatal injection of BM3h-8C8 with an injection of WT BM3h into the opposite hemisphere, following the same blocked K + stimulation paradigm for both injections. As in conventional 'block design' fMRI, we performed a t-test analysis to evaluate the correspondence of each voxel's intensity time course with the alternating periods of low and high K + . We determined an appropriate temporal shift for the stimulus-related analysis windows with respect to infusion buffer switches by observing the time courses of similarly switched mock infusions into 0.6% agarose phantoms 31 and by comparing these with statistical results as a function of offset ( Supplementary Fig. 5 and Online Methods). As additional controls for MRI effects unrelated to dopamine sensing, we examined MRI signal change in response to K + stimulation and again in response to dopamine infusion, both in the absence of contrast agents (data not shown). We also continuously monitored blood oxygen levels and heart rate. In no case were stimulus-associated changes observed. (e) Maps of percent signal difference (SD) between high-and low-K + conditions observed in 2.7-mm-diameter ROIs centered around BM3h-8C8 sensor (left) and WT BM3h control (right) injection sites, after spatial coregistration and averaging across multiple animals (n = 6); ROIs correspond approximately to the color-coded circles in d. Voxels outlined in green are those that showed the most significant correlation with the K + stimulus regressor in the group analysis (Student's t-test, P < 0.01); these generally showed ~1% mean signal change. Gray cross-hatching indicates approximate locations of the infusion cannulae. (f) Mean MRI signal change from baseline observed during high-K + (dark bars) and low-K + (light bars) periods in ROIs centered around infusion sites for BM3h-8C8 (purple) and WT BM3h (gray) proteins. ROIs were cylinders 2.7 mm in diameter and extending over three 1-mm-thick slices registered around the infusion sites; signal was averaged in unbiased fashion over all voxels, regardless of correlation with the stimulus. The signal difference in the presence of BM3h-8C8 was statistically significant (P = 0.0008, asterisk). (g) Graph shows the mean time course of MRI signal in voxels within the BM3h-8C8-infused ROI and identified as correlated (P < 0.05) with the stimulus, averaged over animals and binned over 1.5-min intervals (shaded area denotes s.e.m., n = 6; individual traces are shown in Supplementary Fig. 6 online) . Gray vertical bars denote periods associated with highest K + stimulation, accounting for delays due to convective spreading of K + from the cannulae tips and the dead time of the injection apparatus. Arrowheads indicate the timing of pump switches associated with transitions from low to high (up) and from high to low (down) K + infusion conditions. Panels above the graph depict 'snapshots' of signal change spaced throughout the first K + stimulation cycle, as indicated by the dotted lines. The ROI corresponds to the left side of e, and the color scale denotes 0% (black) to 3% (yellow) signal change from baseline at each voxel and time point. High K + Figure 5d shows the distribution of voxels with significant (t-test, P < 0.01) MRI signal decreases in response to K + stimulation in a single rat. We performed a group analysis by combining data from all subjects (n = 6) over geometrically defined ROIs centered around the injection cannula tips in each animal. In three slices spanning the infusion site, seven voxels within 0.75 mm of the BM3h-8C8 injection cannula, but only one voxel near the WT cannula, showed strong correlation (P < 0.01) with the stimulus. We mapped mean signal decreases over 2.7-mm-diameter ROIs corresponding to the BM3h-8C8 and WT BM3h injection sites in the group analysis (Fig. 5e) . Again, dopamine sensor-dependent responses were apparent. The signal difference between low-and high-K + periods averaged across the entire BM3h-8C8 ROI (all voxels within a 2.7-mm-diameter by 3-mm-long cylinder, regardless of modulation by K + ) was 0.07%, whereas the signal difference averaged across the control ROI was −0.02% (Fig. 5f) . The high-versus low-K + signal difference observed near the BM3h-8C8 infusion site was significant (t-test, P = 0.0008) and consistent with the expected suppression of MRI signal by dopamine release under high-K + conditions.
The mean time course of all stimulus-correlated voxels (P < 0.05) showing K + -induced MRI signal changes near the BM3h-8C8 injection site, averaged over animals, is shown in Figure 5g . Discernable signal decreases of up to 3% were produced during each K + stimulation block. The first K + block evoked the largest response (presumably because of partial dopamine depletion over subsequent blocks 32 ) and elicited a clear spatiotemporal pattern of mean MRI signal change from baseline over the course of the stimulation period (Fig. 5g, top panels) .
DISCUSSION
These results demonstrate the feasibility of developing molecularlevel fMRI sensors and serve as a proof of principle that BM3h-based probes can be used to monitor dopamine signaling processes in vivo. With the experimental conditions and estimated sensor concentrations (34 ± 4 µM) used for our K + stimulation experiments, MRI signal changes of ~3% would be evoked by the rewarding brain stimuli reported in previous studies to release large amounts of dopamine 18, 19 . This amplitude is reasonably large by functional imaging standards, and it could be used in the near term to map phasic dopamine release at high resolution across the striatum, or more generally to study mesolimbic dopamine dynamics in animal models of reward processing and neurological conditions that can be probed with strong stimuli. Sensitivity gains will be possible using repeated stimulation and statistical analysis techniques, as in conventional fMRI, and by optimizing the imaging approach itself. For instance, higher-field scanners and faster alternatives to the T 1 -weighted spin echo pulse sequences we used here may offer improved signal-to-noise ratios. Directed evolution or rational modification of BM3h variants for substantially higher relaxivity is possible as well (unpublished data). Sensors with higher relaxivity will produce larger MRI signal changes, and could have the added benefit of reducing the potential for dopamine buffering, because they may be used at lower concentrations in vivo: with 35 µM sensor and 35 µM total dopamine present, for example, ~60% of the dopamine would be bound to the sensor, but with 15 µM sensor present, only ~30% dopamine would be sequestered. Protein engineering techniques could also be used to improve the dopamine affinity and specificity of the first-generation sensors described here.
Our method for producing dopamine sensors represents a general paradigm for the development of molecular probes for MRI. Sensors may be evolved for targets inside or outside the brain; the diversity of potential targets is exemplified by the contrast between WT BM3h, which produces MRI signal changes in response to long-chain fatty acids, and BM3h-8C8 and BM3h-B7, which respond to a catecholamine. Contrast agents engineered to detect dopamine and other signaling molecules in the brain will permit functional neuroimaging based on direct detection of neuronal events rather than hemodynamic changes. Exogenous delivery of macromolecules such as BM3h to large regions of animal brains should be possible using a variety of techniques 33 . Because BM3h is a protein, it might also be possible to deliver variants via expression from transfected cells in vivo or in transgenic subjects. Preliminary evidence that BM3h can be expressed to 1% protein content in mammalian cells supports the feasibility of this approach (Supplementary Results). Because of their small size, BM3h-based dopamine sensors might sample synaptic dopamine better than voltammetry or microdialysis probes, and with appropriate targeting could potentially become synapse specific. Dopamine sensor-dependent MRI would offer a combination of spatial coverage and precision inaccessible to other methods and uniquely suited to studies of dopaminergic function in systems neuroscience research.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. Library construction. We constructed BM3h mutant libraries in accordance with a previously published protocol 7 . The starting parent for evolution was the WT heme domain of BM3 with a C-terminal hexahistidine tag, housed in the pCWori vector 35 . We produced mutant libraries through error-prone PCR using the primers 5′-GAAACAGGATCCATCGATGCTTAGGAGGTCAT-3′ (forward) and 5′-GCTCATGTTTGACAGCTTATCATCG-3′ (reverse) and Taq polymerase (AmpliTaq, Applied Biosystems) with 25 µM MnCl 2 , producing ~1-2 mutations per gene. Between the fourth and fifth rounds of evolution, we introduced the mutation I366V into BM3h-8C8 via overlap extension PCR to improve protein thermostability 27 .
Protein expression and high-throughput screening. We inoculated mutant colonies into deep-well 96-well plates containing 0.4 ml Luria broth (LB) medium and grew them overnight. On each plate, we included the parent clone and up to three previous parents in triplicate. We then transferred 0.1 ml of each culture to new plates containing 1.2 ml fresh terrific broth (TB) medium per well, supplemented with 100 µg ml −1 ampicillin, 0.2 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) and 0.5 mM δ-aminolevulinic acid (ALA). We stored remaining LB cultures with glycerol at −80 °C. After 20-30 h of protein expression at 30 °C, we pelleted cultures and lysed the pellets in 0.65 ml PBS containing 0.75 mg ml −1 hen egg lysozyme (Sigma-Aldrich) and 5 µg ml −1 DNase I (Sigma-Aldrich). We recorded absorbance spectra of 200 µl of cleared lysate from each well in a multiwell plate reader (Spectramax Plus, Molecular Devices) before and after addition of successively more concentrated dopamine or arachidonic acid. We analyzed the resulting absorbance spectra in Matlab (Mathworks) using a custom routine that calculated the absorbance difference spectra for each acquisition relative to ligand-free lysate, computed the difference between maximum and minimum of each difference spectrum, plotted each value as a function of ligand concentration and, for each well, fitted a non-ligand-depleting bimolecular association function to estimate the corresponding K d . We subsequently compared mutant K d values to those of the parents within each plate and chose eight to ten mutants showing the greatest decrease in K d for dopamine and/or the greatest increase in K d for arachidonic acid for bulk expression and analysis.
Bulk expression and titrations. To produce selected proteins in bulk, we began by inoculating frozen LB cultures of candidate mutants into 30 ml TB medium containing 100 µg ml −1 ampicillin. We induced the cultures at log phase with 0.6 mM IPTG, supplemented them with 0.5 mM ALA and 50 µg ml −1 thiamine and shook them for an additional 20-25 h to express protein.
We then lysed pelleted cells with BugBuster and Lysonase (EMD Chemicals) and purified BM3h mutants over Ni-NTA agarose (Qiagen). We exchanged buffer to PBS over PD-10 desalting columns (GE Healthcare), and measured protein concentration using a carbon monoxide binding assay 36 . To characterize ligand affinities of the purified variants, we titrated protein samples with dopamine, arachidonic acid, serotonin, norepinephrine, pyrocatechol, 3,4-dihydroxy-l-phenylalanine (DOPA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 3-methoxytyramine (3MT), acetylcholine, glutamate, glycine, GABA and epinephrine (all from Sigma Aldrich) and analyzed the results using Matlab as described above. We performed all measurements at room temperature (~21 °C). 3MT had a K d of 73 ± 13 µM for BM3h-B7 and 183 ± 28 µM for BM3h-8C8. HVA and pyrocatechol showed no measurable affinity.
In vitro magnetic resonance imaging. To assess magnetic relaxation behavior of the proteins, we arrayed BM3h samples (60-100 µl) into microtiter plates and placed them in a 40-cm-bore Bruker Avance 4.7 T MRI scanner, equipped with a 10-cm-inner-diameter birdcage resonator radiofrequency coil and 26 G cm −1 triple-axis gradients. We filled unused wells of the microtiter plates with PBS and performed imaging at ~21 °C on a 2-mm slice through the sample. We used a T 1 -weighted spin echo pulse sequence; echo time (TE) was 10 ms, and repetition times (TR) were 73, 116, 186, 298, 477, 763 ms, 1.221, 1.953, 3.125 and 5.000 s. Data matrices consisted of 512 × 128 points, zero-filled to 1,024 × 512 points, where the second dimension corresponds to the phaseencoding direction; the field of view (FOV) was 16 × 8 cm. We reconstructed and analyzed images using custom routines running in Matlab and adjusted contrast to optimize MRI images presented in the figures. We calculated relaxation rates by exponential fitting to the image data, using an equation of the form I = k[1 -exp(−TR/T1)], where I was the observed MRI signal intensity and k was a constant of proportionality. We then determined values of r 1 by linear fitting to a plot of R 1 against protein concentration for six to eight BM3h concentrations in the range from 0 to 240 µM. We also performed low-field relaxivity measurements using benchtop spectrometers operating at 21 °C with proton resonance frequencies of 20 MHz and 60 MHz (Bruker Minispec NMS120 and mq60). Samples of 150 µL containing 50-100 µM BM3h-8C8 in PBS in the absence or presence of 500 µM dopamine yielded 20-MHz relaxivity measurements of 1.0 or 0.25 mM −1 s −1 , respectively, and 60-MHz relaxivities of 1.1 or 0.23 mM −1 s −1 , respectively. Dopamine release from PC12 cells. We grew PC12 cells in suspension in F-12K medium supplemented with 15% (vol/vol) horse serum and 2.5% (vol/vol) FBS (ATCC). In preparation for dopamine release experiments, we incubated 50-ml cell cultures for 1 h in medium supplemented with 1 mM dopamine and 1 mM ascorbic acid, pelleted the cells and washed them twice with Locke's buffer (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO 3 , 2.3 mM CaCl 2 , 5.6 mM d-glucose and 5 mM HEPES pH 7.4). To Locke's buffer missing 54 mM NaCl and containing or not containing the sensor, we added a 1:50 dilution of 2.7 M KCl (stimulus) or NaCl (control). We resuspended the washed PC12 cell pellets in 200 µl of either K + -or Na + -supplemented buffer, with or without sensor. After 30-60 min incubation at ~21 °C, we pelleted cells and imaged the supernatant in an MRI scanner as described above. We estimated dopamine release by calculating sensor saturation level from observed r 1 , then solving the quadratic equation describing bimolecular equilibrium binding with a known K d , and assuming 32 µM of sensor for ligand concentration. We made independent measurements of dopamine release using the Dopamine EIA Kit (LDN).
Brain injection of sensors with exogenous dopamine. For injection experiments testing the effect of exogenous dopamine on BM3h-8C8 and WT BM3h (Fig. 5a-c) , we anesthetized adult male Lewis rats with 1-2% isoflurane. We stereotaxically inserted plastic guide cannulae (Plastics One) bilaterally into the striatum and secured them in place with dental cement (coordinates with respect to bregma: +0.7 mm anterior, 3 mm lateral, 6 mm below the surface of the skull). We connected tubing filled with silicone oil to an MRI-compatible dual channel syringe pump (Harvard Apparatus), attached it to internal cannulae and back-filled the cannulae with contrast agent solution, 500 µM BM3h-8C8 or WT BM3h, with or without equimolar dopamine (chemicals from Sigma-Aldrich). We ran the pump in infusion mode for a few seconds to ensure that no air entered the system and then lowered the internal cannulae (connected to the pump) into the implanted guide cannulae and fixed them in place with dental cement. After the implantation was complete, we transferred the animal to a plastic positioning device (Ekam Imaging) for imaging and placed it into a 4.7-T Bruker Avance scanner. We acquired fast spin echo (FSE) MRI scans (TE/TR 14/277 ms, 8.9 s per scan, 0.3 × 0.3 × 1.0 mm resolution, 3.8 × 3.8 cm FOV, data matrix 128 × 128) before infusion (seven scans) and continuously during and after bilateral infusion of paired solutions, each injected for 20 min at 0.5 µl min −1 . We monitored heart rate continuously during the infusions using a Nonin Medical 8600V pulse oximeter equipped with a nonmagnetic sensor. We digitized raw oximetry readings using a National Instruments USB-6008 interface and converted them to heart rate using a Matlab code. Values were stable at around 350 beats per minute ± 40 (s.d.).
We analyzed MRI data from these experiments using custom routines running in Matlab. We detrended image signal time courses, converted them to percent change with respect to the preinjection baseline and averaged them over striatal ROIs. ROIs were chosen to approximate the maximal volumes reliably filled with the contrast agent, and were defined by a five-voxel in-plane radius (2.7 mm diameter) around the cannula tips over three image slices centered rostrocaudally around the implantation position, excluding voxels with notable signal dropout due to the cannulae themselves. We produced data for group analyses by combining data from ROIs defined separately with respect
